TY - JOUR
T1 - Treating colon cancers with a non-conventional yet strategic approach
T2 - An overview of various nanoparticulate systems
AU - Bhaskaran, N. A.
AU - Kumar, L.
N1 - Funding Information:
Authors are thankful to Science and Engineering Research Board (SERB), New Delhi (Grant Number - EMR/2016/003893 ) and Indian Council of Medical Research (ICMR), New Delhi (Grant Number - 45/15/2020-Nan/BMS ) for financial support in relavant area of research. Authors are also thankful to Manipal College of Pharmaceutical Sciences, Manipal and Manipal Academy of Higher Education, Manipal for providing infrastructural facilities to complete this manuscript.
Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/8/10
Y1 - 2021/8/10
N2 - Regardless of progress in therapy management which are developed for colon cancer (CC), it remains the third most common cause of mortality due to cancers around the world. Conventional medicines pose side effects due to untoward action on non-target cells. Their inability to deliver drugs to the affected regions of the colon locally, in a reproducible manner raises a concern towards the efficacy of therapy. In this regard, nanoparticles emerged as a promising drug delivery system due to their flexibility in designing, drug release modulation and cancer cell targeting. Not only are nanoparticles making their way into colon cancer research in the revolution of conventional onco-therapeutics, but they also offer promising scope in the development of colon cancer vaccines and theranostic tools. However, there are challenges with respect to drug delivery using nanoparticles, which may hamper the delivery of these novel carriers to the colon. The present review addresses recent advents in nanotechnology for colon-specific drug delivery (CDDS) which may help to overcome the existing challenges and intends to recognize futuristic potentials in the treatment of CC with CDDS.
AB - Regardless of progress in therapy management which are developed for colon cancer (CC), it remains the third most common cause of mortality due to cancers around the world. Conventional medicines pose side effects due to untoward action on non-target cells. Their inability to deliver drugs to the affected regions of the colon locally, in a reproducible manner raises a concern towards the efficacy of therapy. In this regard, nanoparticles emerged as a promising drug delivery system due to their flexibility in designing, drug release modulation and cancer cell targeting. Not only are nanoparticles making their way into colon cancer research in the revolution of conventional onco-therapeutics, but they also offer promising scope in the development of colon cancer vaccines and theranostic tools. However, there are challenges with respect to drug delivery using nanoparticles, which may hamper the delivery of these novel carriers to the colon. The present review addresses recent advents in nanotechnology for colon-specific drug delivery (CDDS) which may help to overcome the existing challenges and intends to recognize futuristic potentials in the treatment of CC with CDDS.
UR - http://www.scopus.com/inward/record.url?scp=85107919911&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107919911&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2021.06.008
DO - 10.1016/j.jconrel.2021.06.008
M3 - Review article
AN - SCOPUS:85107919911
SN - 0168-3659
VL - 336
SP - 16
EP - 39
JO - Journal of Controlled Release
JF - Journal of Controlled Release
ER -